Advertisement

Medicinal Chemistry Research

, Volume 28, Issue 10, pp 1633–1647 | Cite as

Discovery of 3-(thiophen/thiazole-2-ylthio)pyridine derivatives as multitarget anticancer agents

  • Jiankang Zhang
  • Jianjun Xi
  • Ruoyu He
  • Rangxiao Zhuang
  • Limin Kong
  • Liping Fu
  • Yanmei Zhao
  • Chong Zhang
  • Linghui Zeng
  • Jingyi Lu
  • Rujia Tao
  • Zhengmengtong Liu
  • Huajian ZhuEmail author
  • Shourong LiuEmail author
Original Research
  • 40 Downloads

Abstract

A series of novel 3-(thiophen/thiazole-2-ylthio)pyridine derivatives were designed and synthesized as IGF-1R tyrosine kinase inhibitors. All the target compounds were tested for their IGF-1R kinase inhibitory activities and cytotoxicities against five cancer cell lines (K562, Hep-G2, HCT-116, WSU-DLCL2, and A549). Although all these compounds exhibited moderate to potent cancer cell proliferation inhibitory activities (the most potent compound 43 showed IC50 value of 1.3 ± 0.9 μM against WSU-DLCL2 cell line), IGF-1R inhibition were not observed. In order to identify the exact target of these analogues, selected compounds were further screened for various kinases. The results indicated that this series of compounds may exert their anticancer activities through inhibiting various kinases including FGFR 3, EGFR, JAK, and RON. In addition, cell cycle analysis of compound 43 on Hep-G2 cells showed cell cycle arrest at G1/G0 phase. All the experiments validated the potential of 3-(thiophen/thiazole-2-ylthio)pyridine analogues as multi-target anticancer agents.

Keywords

Multitarget IGF-1R Anti-cancer Kinases 

Notes

Acknowledgements

The authors thank the project supported by the key Development Program of the Hangzhou Science and Technology Committee (Grant No. 20152013A03), the Research project on application of public welfare technology supported by Science Technology Department of Zhejiang Province (Grant No. 2017C33233 and LGF18H300001).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Brahmkhatri VP, Prasanna C, Atreya HS (2015) Insulin-like growth factor system in cancer: novel targeted therapies. Biomed Res Int 2015:538019CrossRefGoogle Scholar
  2. Buchanan JL, Newcomb JR, Carney DP, Chaffee SC, Chai L, Cupples R, Epstein LF, Gallant P, Gu Y, Harmange JC, Hodge K, Houk BE, Huang X, Jona J, Joseph S, Jun HT, Kumar R, Li C, Lu J, Menges T, Morrison MJ, Novak PM, van der Plas S, Radinsky R, Rose PE, Sawant S, Sun JR, Surapaneni S, Turci SM, Xu K, Yanez E, Zhao H, Zhu X (2011) Discovery of 2, 4-bis-arylamino-1, 3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors. Bioorg Med Chem Lett 21:2394–2399CrossRefGoogle Scholar
  3. Carboni JM, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W, Hillerman S, Cao C, Cantor GH, Dell-John J, Chen C, Discenza L, Menard K, Li A, Trainor G, Vyas D, Kramer R, Attar RM, Gottardis MM (2009) BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 8:3341–3349CrossRefGoogle Scholar
  4. Deng XQ, Xiang ML, Jia R, Yang SY (2007) Progress in the design of selective ATP-competitive inhibitors. Acta Pharm Sin 42:1232–1236Google Scholar
  5. Furstenberger G, Senn HJ (2002) Insulin-like growth factors and cancer. Lancet Oncol 3:298–302CrossRefGoogle Scholar
  6. Kawauchi K, Ogasawara T, Yasuyama M, Otsuka K, Yamada O (2009) Regulation and importance of the PI3K/Akt/mTOR signaling pathway in hematologic malignancies. Anticancer Agents Med Chem 9:1024–1038CrossRefGoogle Scholar
  7. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M (2004) Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64:236–242CrossRefGoogle Scholar
  8. Gualberto A, Pollak M (2009) Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets 10:923–936CrossRefGoogle Scholar
  9. Hewish M, Chau I, Cunningham D (2009) Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov 4:54–72CrossRefGoogle Scholar
  10. LeRoith D, Werner H, Beitner-Johnson D, Roberts Jr. CT (1995) Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16:143–163CrossRefGoogle Scholar
  11. Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, O’Connor M, Pirritt C, Sun Y, Yao Y, Arnold LD, Gibson NW, Ji QS (2009) Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 1:1153–1171CrossRefGoogle Scholar
  12. Pollak M, Beamer W, Zhang JC (1998) Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 17:383–390CrossRefGoogle Scholar
  13. Rodon J, DeSantos V, Ferry Jr RJ, Kurzrock R (2008) Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 7:2575–2588CrossRefGoogle Scholar
  14. Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6:1–12CrossRefGoogle Scholar
  15. Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20–47CrossRefGoogle Scholar
  16. Scagliotti GV, Novello S (2012) The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev 38:292–302CrossRefGoogle Scholar
  17. Sepp-Lorenzino L (1998) Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res Treat 47:235–253CrossRefGoogle Scholar
  18. Stewart CE, Rotwein P (1996) Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 76:1005–1026CrossRefGoogle Scholar
  19. Sun WY, Yun HY, Song YJ, Kim H, Lee OJ, Nam SJ, Koo JS (2015) Insulin-like growth factor 1 receptor expression in breast cancer tissue and mammographic density. Mol Clin Oncol 3:572–580CrossRefGoogle Scholar
  20. Sun Y, Sun X, Shen B (2017) Molecular Imaging of IGF-1R in Cancer. Mol Imaging 16:1536012117736648CrossRefGoogle Scholar
  21. Treu, M (2010) New aminopyrazoloquinazolines. WO 2,012,010,704(A1).Google Scholar
  22. Trojan J, Cloix JF, Ardourel MY, Chatel M, Anthony DD (2007) Insulin-like growth factor type I biology and targeting in malignant gliomas. Neuroscience 145:795–811CrossRefGoogle Scholar
  23. Vanhaesebroeck B, Alessi DR (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346:561–576Google Scholar
  24. Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoo HK, Lee YS, Lee EJ, Lee KY, Kim TJ (2015) Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. Lung cancer 87:311–317CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.School of MedicineZhejiang University City CollegeHangzhouChina
  2. 2.Department of Pharmaceutical PreparationHangzhou Xixi HospitalHangzhouChina
  3. 3.Department of Pharmacy, The First Affiliated Hospital, College of MedicineZhejiang UniversityHangzhouChina
  4. 4.Department of PharmacyShaoxing Hospital of Traditional Chinese MedicineShaoxingChina

Personalised recommendations